Compare Core Scientific Inc (CORZ) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Crispr Therapeutics AG — how do they compare? Core Scientific Inc trades at $21.29 (market cap $6.35B), while Crispr Therapeutics AG trades at $54.25 (market cap $5.23B). The key difference: Core Scientific Inc is the larger of the two by market cap, and Core Scientific Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CORZ | CRSP | |
|---|---|---|
Market Cap | $6.35B | $5.23B |
Sector | Technology | Health |
52-Week High | $29.16 | $76.78 |
52-Week Low | $13.55 | $44.34 |
Enterprise Value | $8.88B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $21.18, up 8.95% in the last session, amid a technical bearish trend but strong analyst optimism. The company reported Q2 2026 revenue growth and a strategic AMD partnership for AI infrastructure, though it faces significant net losses and negative cash flow. Key support lies at $18, with resistance near $21.
The outlook is mixed: bullish analyst targets near $36 suggest upside potential from AI-driven contracts, but high cash burn and persistent losses pose risks. Investors should weigh growth prospects against financial sustainability, with sentiment hinging on execution of new deals and margin improvement.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
